Abstract:Recent evolution in drug repurposing has brought new anticipation, especially in the conflict against neurodegenerative diseases (NDDs). The traditional approach to developing novel drugs for these complex disorders is laborious, time-consuming, and often abortive. However, drug reprofiling which is the implementation of illuminating novel therapeutic applications of existing approved drugs, has shown potential as a promising strategy to accelerate the hunt for therapeutics. The advancement of computational approaches and artificial intelligence has expedited drug repurposing. These progressive technologies have enabled scientists to analyse extensive datasets and predict potential drug-disease interactions. By prospecting into the existing pharmacological knowledge, scientists can recognise potential therapeutic candidates for reprofiling, saving precious time and resources. Preclinical models have also played a pivotal role in this field, confirming the effectiveness and mechanisms of action of repurposed drugs. Several studies have occurred in recent years, including the discovery of available drugs that demonstrate significant protective effects in NDDs, relieve debilitating symptoms, or slow down the progression of the disease. These findings highlight the potential of repurposed drugs to change the landscape of NDD treatment. Here, we present an overview of recent developments and major advances in drug repurposing intending to provide an in-depth analysis of traditional drug discovery and the strategies, approaches and technologies that have contributed to drug repositioning. In addition, this chapter attempts to highlight successful case studies of drug repositioning in various therapeutic areas related to NDDs and explore the clinical trials, challenges and limitations faced by researchers in the field. Finally, the importance of drug repositioning in drug discovery and development and its potential to address discontented medical needs is also highlighted.

Reductionism and proxy failure: From neuroscience to target-based drug discovery

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

Drug targeting in psychiatric disorders - how to overcome the loss in translation?

Deep learning identifies explainable reasoning paths of mechanism of action for drug repurposing from multilayer biological network

Implementation of functions in R tool in parallel environment

Target-based drug discovery: is something wrong?

Entering the era of computationally driven drug development

Bridging the gap between target-based and phenotypic-based drug discovery

Reimagining old drugs with new tricks: Mechanisms, strategies and notable success stories in drug repurposing for neurological diseases

Identifying patterns to uncover the importance of biological pathways on known drug repurposing scenarios

Recent advances and method development for drug target identification

Revolutionising Neurological Therapeutics: Investigating Drug Repurposing Strategies

Network pharmacology: the next paradigm in drug discovery

Repurposing – second life for drugs

Molecular interaction networks and drug development: Novel approach to drug target identification and drug repositioning

How drug repurposing can advance drug discovery: challenges and opportunities

A Pathway Profile-Based Method for Drug Repositioning

Drug repositioning for orphan diseases.

Repurposing of Drugs: Updates and New Perspectives

The importance of drug target selection capability for new drug innovation: definition, fostering process, and interaction with organizational management

Drug Repurposing: A Leading Strategy for New Threats and Targets